Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 16.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☒ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
Stammdaten
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Unternehmen & Branche
| Name | Metagenomi Therapeutics, Inc. |
|---|---|
| Ticker | MGX |
| CIK | 0001785279 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 50,6 Mio. USD |
| Beta | 0,57 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 25,210,000 | -87,868,000 | -2.36 | 221,103,000 | 158,596,000 |
| 2025-09-30 | 10-Q | 8,659,000 | -20,393,000 | -0.55 | 247,937,000 | 178,447,000 |
| 2025-06-30 | 10-Q | 8,513,000 | -19,908,000 | -0.54 | 272,284,000 | 195,831,000 |
| 2025-03-31 | 10-Q | 4,127,000 | -25,039,000 | -0.68 | 297,866,000 | 212,658,000 |
| 2024-12-31 | 10-K | 52,295,000 | -78,058,000 | -2.36 | 324,599,000 | 234,857,000 |
| 2024-09-30 | 10-Q | 11,514,000 | -18,773,000 | -0.51 | 358,348,000 | 255,773,000 |
| 2024-06-30 | 10-Q | 20,008,000 | -10,739,000 | -0.29 | 385,905,000 | 269,419,000 |
| 2024-03-31 | 10-Q | 11,159,000 | -25,148,000 | -1.19 | 415,403,000 | 275,633,000 |
| 2023-12-31 | 10-K | 44,756,000 | -68,255,000 | -20.05 | 364,842,000 | -135,584,000 |
| 2023-09-30 | 10-Q | 12,363,000 | -19,820,000 | -5.82 | -119,021 | |
| 2023-06-30 | 10-Q | 11,337,000 | -13,008,000 | -3.82 | -102,539,000 | |
| 2023-03-31 | 10-Q | 8,657,000 | -16,133,000 | -4.74 | -90,011,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-05 | Wapnick Pamela | Officer, Chief Financial Officer | Open Market Sale | -1,581 | 1.60 | -2,529.60 | -56,2% | |
| 2026-03-05 | Irish Jian | Director, Officer, Chief Executive Officer | Open Market Sale | -1,607 | 1.60 | -2,571.20 | -57,2% | |
| 2026-03-05 | Wein Matthew | Officer, See Remarks | Open Market Sale | -482 | 1.60 | -771.20 | -17,1% | |
| 2025-12-05 | Thomas Brian C. | Director | Open Market Sale | -3,830 | 1.77 | -6,786.38 | -150,9% | |
| 2025-12-05 | Wein Matthew | Officer, See Remarks | Open Market Sale | -199 | 1.77 | -352.61 | -7,8% | |
| 2025-12-05 | Irish Jian | Director, Officer, Chief Executive Officer | Open Market Sale | -1,602 | 1.77 | -2,838.58 | -63,1% | |
| 2025-12-05 | Wapnick Pamela | Officer, Chief Financial Officer | Open Market Sale | -1,576 | 1.77 | -2,792.51 | -62,1% | |
| 2025-09-05 | Thomas Brian C. | Director | Open Market Sale | -2,701 | 1.81 | -4,888.81 | -108,7% | |
| 2025-09-05 | Wapnick Pamela | Officer, Chief Financial Officer | Open Market Sale | -1,576 | 1.81 | -2,852.56 | -63,4% | |
| 2025-09-05 | Wein Matthew | Officer, See Remarks | Open Market Sale | -199 | 1.81 | -360.19 | -8,0% | |
| 2025-09-05 | Irish Jian | Director, Officer, Chief Executive Officer | Open Market Sale | -1,602 | 1.81 | -2,899.62 | -64,5% | |
| 2025-06-06 | Wapnick Pamela | Officer, Chief Financial Officer | Open Market Sale | -1,576 | 1.75 | -2,758.00 | -61,3% | |
| 2025-06-06 | Noonberg Sarah B. | Officer, Chief Medical Officer | Open Market Sale | -5,239 | 1.75 | -9,168.25 | -203,8% | |
| 2025-06-06 | Thomas Brian C. | Director, Officer, Chief Executive Officer | Open Market Sale | -10,785 | 1.75 | -18,873.75 | -419,6% | |
| 2025-06-06 | Irish Jian | Director, Officer, See Remarks | Open Market Sale | -6,390 | 1.75 | -11,182.50 | -248,6% | |
| 2025-06-06 | Wein Matthew | Officer, See Remarks | Open Market Sale | -199 | 1.75 | -348.25 | -7,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.